Key result
Patients with cancer have an approximately 50% increased risk of atrial fibrillation compared to those without cancer, a risk further heightened by anticancer therapies and surgery.
This review highlights the significant intersection between cancer and atrial fibrillation, noting a 50% increased risk of AF in cancer patients.
Supports closer AF monitoring in cancer care; leaves open optimal prevention strategies pending prospective trials.
Atrial fibrillation (AF) is the most common cardiac arrythmia in adults, affecting 1.5% to 2% of the general population [1]. Its prevalence continues to increase, and as many as 1 in 3 individuals can develop AF in their lifetime [1]. AF is associated with a 2-fold increased risk of thromboembolism and a 6-fold increased risk of congestive heart failure and other cardiovascular complications [2]. Patients with cancer have an ∼50% increased risk of AF compared to those without cancer [3–5]. Many anticancer therapies and/or cancer surgery can heighten the risks of AF.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) conducted an editorial in Atrial fibrillation and cancer. Cancer and anticancer therapies vs. No cancer was evaluated. Patients with cancer have an approximately 50% increased risk of atrial fibrillation compared to those without cancer, a risk further heightened by anticancer therapies and surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: